Leaky Gut Research Stack

Leaky Gut Stack – BPC‑157, TB‑500, and KPV for Gut Barrier Research

The Leaky Gut Stack combines BPC‑157, TB‑500, and KPV into a coordinated protocol intended for research on intestinal permeability, mucosal healing, and systemic inflammatory load. Each peptide contributes a distinct but complementary mechanism: BPC‑157 for mucosal and vascular repair, TB‑500 for cell migration and angiogenesis, and KPV for targeted anti‑inflammatory signaling along the gut–immune axis.

Key components and roles

• BPC‑157: A stable gastric pentadecapeptide studied for its ability to support GI mucosal integrity, microvascular repair, and tissue regeneration in models of ulcers, colitis, and gut injury. Often used to investigate reduced permeability, improved healing of the intestinal lining, and protection of the gut–vascular interface.

• TB‑500 (Thymosin Beta‑4 fragment): A thymosin‑beta‑4–inspired peptide associated with enhanced cell migration, actin remodeling, and new‑vessel formation. In gut‑adjacent and systemic models, it is used to study how improved angiogenesis and soft‑tissue repair may support recovery of the gut wall and surrounding connective tissues.

• KPV (Lys‑Pro‑Val): A melanocortin‑derived tripeptide with potent anti‑inflammatory actions, commonly used to examine suppression of NF‑κB‑driven cytokines, reduced neutrophil infiltration, and improved epithelial barrier function in colitis and “leaky gut”–type models.

Together, these three peptides allow researchers to probe both structural (epithelial and connective‑tissue repair, angiogenesis) and functional (cytokine balance, barrier permeability) aspects of intestinal health in a single stack.

Research applications

This Leaky Gut Stack is suited for experimental systems investigating:

• Intestinal permeability and “leaky gut” models, including chemically induced colitis or barrier disruption, with endpoints such as tight‑junction protein expression, histology, and permeability assays.

• Gut‑driven inflammation and immune activation, where cytokine profiles, myeloperoxidase activity, and systemic inflammatory markers are tracked under combined barrier‑repair and anti‑inflammatory support.

• Post‑injury or post‑procedure GI recovery, exploring how simultaneous support for mucosal healing, vascular supply, and inflammation modulation may influence recovery trajectories.

• Broader gut–joint–skin paradigms, where improvements in barrier integrity are studied alongside changes in extra‑intestinal tissues linked to chronic inflammation.

  
  

Recommended handling

• For controlled laboratory research use only, by qualified professionals.

• Store each peptide (BPC‑157, TB‑500, KPV) in a cool, dry environment away from light; follow institutional SOPs for peptide storage, reconstitution, aliquoting, and disposal.

• Investigators should design dosing schedules and routes of administration based on existing data for each peptide individually and the specific gut or systemic model being used.

  
  

Important disclaimer

All compounds sold by Rocky Peptide Chain, including the Leaky Gut Stack (BPC‑157, TB‑500, and KPV), are for research use only. They are not intended for human consumption, medical use, diagnostic purposes, or treatment of any disease or condition. No claims are made or implied regarding gut healing, symptom relief, immune modulation, or therapeutic benefit. Researchers are solely responsible for appropriate handling, experimental design, and compliance with all applicable regulations.